Tumour biomarker changes after neoadjuvant chemotherapy in breast cancer - European Medical Journal

Tumour biomarker changes after neoadjuvant chemotherapy in breast cancer

Oncology

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD, from the German Breast Group, Neu-Isenburg, Germany, discusses changes in tumour expression of HER2 and hormone receptor status and pathological complete response (pCR) after neoadjuvant chemotherapy in a Japanese breast cancer registry.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now